MX2009007065A - Variantes de desintegrina y usos farmaceuticos de los mismos. - Google Patents
Variantes de desintegrina y usos farmaceuticos de los mismos.Info
- Publication number
- MX2009007065A MX2009007065A MX2009007065A MX2009007065A MX2009007065A MX 2009007065 A MX2009007065 A MX 2009007065A MX 2009007065 A MX2009007065 A MX 2009007065A MX 2009007065 A MX2009007065 A MX 2009007065A MX 2009007065 A MX2009007065 A MX 2009007065A
- Authority
- MX
- Mexico
- Prior art keywords
- disintegrin
- integrin
- angiogenesis
- variant
- retinopathy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen variantes de desintegrina y usos farmacéuticos de las mismas. La variante de desintegrina incluye un polipéptido aislado que tiene una actividad antagonista del receptor de integrina avß3 y una actividad substancialmente reducida del bloqueo del receptor de integrina alIbß3 y/o a5ß1 comparado con la desintegrina de tipo natural. La variante es codificada por una secuencia de nucleótidos de desintegrina modificada que codifica una secuencia de aminoácidos modificada, que da como resultado un polipéptido que tiene una afinidad substancialmente reducida a la integrina allbß3 y/o a5ß1 comparada con la desintegrina de tipo natural. La variante es útil para el tratamiento y/o prevención de enfermedades asociadas con la integrina avß3 en un mamífero, las cuales incluyen osteoporosis, crecimiento de tumor del hueso o cáncer, crecimiento y metástasis del tumor relacionados con la angiogénesis, metástasis de tumores en los huesos, hipercalcemia inducida por las malignidades, enfermedades de los ojos relacionadas con la angiogénesis, la enfermedad de Paget, artritis reumática y osteoartritis. Las enfermedades del ojo relacionadas con la angiogénesis incluyen degeneración macular relacionada con la edad, retinopatía diabética, enfermedades de neovascularización de la córnea, retinopatía neovascularizadora inducida por isquemia, alta miopía, y retinopatía de premadurez.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87185406P | 2006-12-26 | 2006-12-26 | |
| PCT/US2007/026125 WO2008088548A2 (en) | 2006-12-26 | 2007-12-21 | Disintegrin variants and pharmaceutical uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009007065A true MX2009007065A (es) | 2009-10-13 |
Family
ID=39636522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009007065A MX2009007065A (es) | 2006-12-26 | 2007-12-21 | Variantes de desintegrina y usos farmaceuticos de los mismos. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7943728B2 (es) |
| EP (2) | EP2124548B1 (es) |
| JP (3) | JP5908666B2 (es) |
| KR (1) | KR20090108049A (es) |
| CN (1) | CN101677537B (es) |
| AU (1) | AU2007343734B2 (es) |
| BR (1) | BRPI0720636A2 (es) |
| CA (1) | CA2672091A1 (es) |
| ES (1) | ES2389697T3 (es) |
| HK (1) | HK1136160A1 (es) |
| IL (1) | IL199564A (es) |
| MX (1) | MX2009007065A (es) |
| NZ (2) | NZ577998A (es) |
| RU (2) | RU2477727C2 (es) |
| TW (1) | TWI392738B (es) |
| WO (1) | WO2008088548A2 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7943728B2 (en) * | 2006-12-26 | 2011-05-17 | National Cheng Kung University | Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases |
| CN101481412B (zh) * | 2009-02-09 | 2011-08-10 | 吉林大学 | 一种具有抗肿瘤作用的多肽及其编码基因与应用 |
| RU2547592C2 (ru) * | 2009-07-20 | 2015-04-10 | Нэйшнл Ченг Кунг Юниверсити | ПОЛИПЕПТИДЫ, СЕЛЕКТИВНЫЕ В ОТНОШЕНИИ ИНТЕГРИНА αvβ3, КОНЪЮГИРОВАННЫЕ С ВАРИАНТОМ ЧЕЛЕВЕЧЕСКОГО СЫВОРОТОЧНОГО АЛЬБУМИНА (HSA), И ИХ ФАРМАЦЕВТИЧЕСКИЕ ПРИМЕНЕНИЯ |
| US20120264212A1 (en) * | 2009-11-06 | 2012-10-18 | Virginia Tech Intellectual Properties, Inc. | Compounds and methods for inhibiting the metastasis of cancer cells |
| US9044436B2 (en) * | 2009-12-23 | 2015-06-02 | National Cheng Kung University | Compositions and methods for the treatment of angiogenesis-related eye diseases |
| CN103327996B (zh) * | 2010-11-01 | 2016-06-15 | 延世大学校产学协力团 | 血栓溶解用组合物及包含其的血管狭窄或闭塞性疾病的治疗用药剂学组合物 |
| WO2015016616A1 (ko) | 2013-07-30 | 2015-02-05 | 연세대학교 산학협력단 | 삭사틸린-Ｆｃ 융합 단백질 및 이의 용도 |
| KR101724129B1 (ko) * | 2014-03-28 | 2017-04-10 | 연세대학교 산학협력단 | Rgd 모티프를 포함하는 펩타이드 또는 단백질을 포함하는 신경염증 예방, 억제 또는 치료용 조성물 |
| TWI563001B (en) * | 2014-08-22 | 2016-12-21 | Univ Nat Cheng Kung | Disintegrin variants and pharmaceutical uses thereof |
| US10463720B2 (en) | 2014-12-31 | 2019-11-05 | Huons Co., Ltd. | Composition, containing RGD motif-containing peptide or fragment thereof, for treating burns and glaucoma, alleviating skin wrinkles, and promoting hair growth |
| CN104774247B (zh) * | 2015-04-20 | 2018-06-05 | 中国药科大学 | 与整合素受体αvβ3相关的5肽 |
| CA2987884C (en) * | 2015-06-28 | 2023-01-03 | Allgenesis Biotherapeutics Inc. | Fusion peptides comprising disintegrin binding to integrin .alpha.v.beta.x or .alpha.5.beta.1 and their use in treating an angiogenic disease |
| WO2018048477A1 (en) * | 2016-09-06 | 2018-03-15 | Debina Diagnostics, Inc. | Engineering and utility of fluorescent nanodiamond particles (ndp-f) for diagnostics and treatment of blood clots in human and veterinary medicine |
| US11085920B2 (en) | 2016-09-06 | 2021-08-10 | Debina Diagnostics, Inc. | Nanodiamond particles and related devices and methods |
| EP3665190B1 (en) * | 2017-08-09 | 2023-07-26 | National Taiwan University | Disintegrin variants and uses thereof |
| CA3144004A1 (en) * | 2019-06-18 | 2020-12-24 | Debina Diagnostics, Inc. | Compositions and articles comprising (nano)diamond particles |
| BR102021016135A2 (pt) * | 2021-08-16 | 2023-02-23 | Novageia Biotecnologia Ltda | Antagonistas miméticos macrocíclicos com atividade biológica, seus usos e composições |
| US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) * | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) * | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) * | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) * | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) * | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| EP0382451A3 (en) * | 1989-02-07 | 1991-05-29 | Merck & Co. Inc. | Viper venom polypeptides and variants |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| JPH05255395A (ja) * | 1990-10-26 | 1993-10-05 | Takeda Chem Ind Ltd | ポリペプチドおよびその製造法 |
| US5380646A (en) * | 1992-10-19 | 1995-01-10 | Temple University Of The Commonwealth System Of Higher Education | Thrombus detection using radiolabelled disintegrins |
| US6710030B1 (en) | 1993-10-22 | 2004-03-23 | University Of Southern California | Contortrostain (CN) and methods for its use in preventing metastasis and other conditions |
| US5786324A (en) * | 1994-03-24 | 1998-07-28 | Regents Of The University Of Minnesota | Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use |
| US5770565A (en) * | 1994-04-13 | 1998-06-23 | La Jolla Cancer Research Center | Peptides for reducing or inhibiting bone resorption |
| ATE464892T1 (de) * | 2000-02-03 | 2010-05-15 | Eisai R&D Man Co Ltd | Inhibitoren der integrinexpression |
| WO2003104243A1 (en) * | 2002-06-07 | 2003-12-18 | Wisconsin Alumni Research Foundation | Chemical synthesis of reagents for peptide coupling |
| US7271245B2 (en) * | 2004-02-13 | 2007-09-18 | The Scripps Research Institute | Methods and compositions for inhibition of metastasis |
| EP2634252B1 (en) * | 2005-02-11 | 2018-12-19 | University of Southern California | Method of expressing proteins with disulfide bridges |
| US7943728B2 (en) * | 2006-12-26 | 2011-05-17 | National Cheng Kung University | Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases |
-
2007
- 2007-12-20 US US12/004,045 patent/US7943728B2/en not_active Expired - Fee Related
- 2007-12-21 CA CA002672091A patent/CA2672091A1/en not_active Abandoned
- 2007-12-21 JP JP2009544049A patent/JP5908666B2/ja active Active
- 2007-12-21 ES ES07867921T patent/ES2389697T3/es active Active
- 2007-12-21 BR BRPI0720636-4A patent/BRPI0720636A2/pt not_active IP Right Cessation
- 2007-12-21 WO PCT/US2007/026125 patent/WO2008088548A2/en active Application Filing
- 2007-12-21 CN CN200780051774.5A patent/CN101677537B/zh not_active Expired - Fee Related
- 2007-12-21 RU RU2009128647/10A patent/RU2477727C2/ru not_active IP Right Cessation
- 2007-12-21 AU AU2007343734A patent/AU2007343734B2/en not_active Ceased
- 2007-12-21 NZ NZ577998A patent/NZ577998A/en not_active IP Right Cessation
- 2007-12-21 MX MX2009007065A patent/MX2009007065A/es active IP Right Grant
- 2007-12-21 EP EP07867921A patent/EP2124548B1/en not_active Not-in-force
- 2007-12-21 NZ NZ598176A patent/NZ598176A/xx not_active IP Right Cessation
- 2007-12-21 KR KR1020097015644A patent/KR20090108049A/ko not_active Application Discontinuation
- 2007-12-21 EP EP20120171692 patent/EP2522676A3/en not_active Withdrawn
- 2007-12-25 TW TW096150026A patent/TWI392738B/zh active
-
2009
- 2009-06-25 IL IL199564A patent/IL199564A/en not_active IP Right Cessation
-
2010
- 2010-03-30 HK HK10103274.9A patent/HK1136160A1/xx not_active IP Right Cessation
-
2012
- 2012-11-16 RU RU2012148887/10A patent/RU2012148887A/ru not_active Application Discontinuation
-
2013
- 2013-02-20 JP JP2013031102A patent/JP2013151502A/ja active Pending
-
2015
- 2015-08-28 JP JP2015168912A patent/JP2016047818A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HK1136160A1 (en) | 2010-06-25 |
| JP2016047818A (ja) | 2016-04-07 |
| EP2124548A2 (en) | 2009-12-02 |
| ES2389697T3 (es) | 2012-10-30 |
| CN101677537B (zh) | 2016-08-17 |
| BRPI0720636A2 (pt) | 2014-01-07 |
| WO2008088548A2 (en) | 2008-07-24 |
| JP2013151502A (ja) | 2013-08-08 |
| NZ577998A (en) | 2012-03-30 |
| TWI392738B (zh) | 2013-04-11 |
| AU2007343734B2 (en) | 2014-01-30 |
| CN101677537A (zh) | 2010-03-24 |
| KR20090108049A (ko) | 2009-10-14 |
| RU2012148887A (ru) | 2014-05-27 |
| IL199564A (en) | 2015-05-31 |
| AU2007343734A2 (en) | 2009-09-03 |
| RU2009128647A (ru) | 2011-02-10 |
| JP2010514444A (ja) | 2010-05-06 |
| EP2522676A2 (en) | 2012-11-14 |
| RU2477727C2 (ru) | 2013-03-20 |
| US7943728B2 (en) | 2011-05-17 |
| JP5908666B2 (ja) | 2016-04-26 |
| EP2522676A3 (en) | 2013-02-27 |
| AU2007343734A1 (en) | 2008-07-24 |
| TW200848070A (en) | 2008-12-16 |
| WO2008088548A3 (en) | 2008-10-16 |
| CA2672091A1 (en) | 2008-07-24 |
| EP2124548B1 (en) | 2012-06-13 |
| EP2124548A4 (en) | 2010-05-05 |
| NZ598176A (en) | 2013-08-30 |
| US20080188413A1 (en) | 2008-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009007065A (es) | Variantes de desintegrina y usos farmaceuticos de los mismos. | |
| WO2003104270A3 (en) | GENES OF DUDULINE 2, EXPRESSION PRODUCTS, NON-HUMAN ANIMAL MODEL: USES IN HUMAN HEMATOLOGICAL DISEASES | |
| IN2014DN05670A (es) | ||
| NZ586003A (en) | Antigen binding proteins that bind beta-amyloid peptide | |
| WO2007089375A3 (en) | Compositions and methods for regulating complement system | |
| MX2010003774A (es) | Formulaciones oftalmicas acuosas. | |
| BRPI0519508A2 (pt) | análogos de aminopirazina para tratamento de glaucoma e outras doenças ou condições mediadas por rho cinase | |
| MX2009003729A (es) | Copuestos antagonistas de acido ribonucleico para la modulacion de proproteina convertasa subtilisina/kexina tipo 9a. | |
| DK2459216T3 (da) | Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer | |
| MX2012005131A (es) | Enfoques terapeuticos nuevos para tratar la enfermedad de alzheimer. | |
| DE60141409D1 (de) | Homologe des nogo rezeptors | |
| WO2010010551A3 (en) | Angiopoietin derived peptides | |
| MX2012007416A (es) | Composiciones y metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis. | |
| EP2377558A4 (en) | COMPOSITION TO TREAT INFLAMMATORY DISEASES WITH ABH ANTIGENES | |
| MX2013012661A (es) | Compuestos de piridazina biciclicos como inhibidores pim. | |
| EA200901067A1 (ru) | Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов | |
| ES2572835T3 (es) | Fragmento de agrina modificado capaz de restituir la fuerza muscular, para su uso como medicamento | |
| MX2021007434A (es) | Peptidos de colageno producidos de forma sintetica y recombinante con eficacia biologica. | |
| NZ596433A (en) | Protein product and process for preparing injectable protein product | |
| NZ596434A (en) | Protein product and process for making injectable protein product | |
| MX2021010264A (es) | Formulaciones estables de proteina. | |
| BR112015003947A2 (pt) | proteínas de fusão e métodos para tratar, prevenir ou melhorar dor | |
| EA201170917A1 (ru) | Ген, кодирующий мутантную глюкокиназу человека, кодируемый им фермент, рекомбинантные векторы и хозяева, фармацевтические композиции и их применения, способы лечения и предупреждения болезней | |
| DK2407536T3 (da) | Adp-ribosyltransferase-fusionsvariantproteiner | |
| JP2015504304A (ja) | ポリ−グリシンを伴う修飾神経毒及びその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FG | Grant or registration | ||
| GB | Transfer or rights |